

DAFTAR PUSTAKA

- ACOG, (2013). Hypertension in pregnancy. Washington DC: American College of Obstetricians and Gynecologists.
- Al-Bayati, M., Ahmad, M. & Khamas, W., (2014). The potential effect of L-arginine on mice placenta. *Advances in Pharmacoeidemiology & Drug Safety*, 3(2), pp.1-9.
- Babaei, S. & Stewart, D., (2002). Overexpression of endothelial NO synthase induces angiogenesis in a co-culture model. *Cardiovascular Research*, 55, pp.190-200.
- Baksu, B., (2005). Plasma nitric oxide, endothelin-1 and urinary nitric oxide and cyclic guanosine monophosphate levels in hypertensive pregnant women. *International Journal of Gynecology & Obstetrics*, 90(2), pp.112-17
- Blum A, Porat R, Rosenschein U, Keren G, Roth A, Laniado S, Miller H. 1999. Clinical and inflammatory effects of dietary L-Arginine in patients with intractable angina pectoris. *Am J Cadiology*. 1999. 83(10): 1488-90.
- Boger, R., (2008). The Pharmacodynamics of L-Arginine. *The Journal of Nutrition*, 137(6), pp.1650S-5S.
- Brennan, J., Morton, J., Davidge, S. 2014. Vascular Dysfunction in Preeclampsia". *Microcirculation* 21: 4-14
- Burke, S. & Karumanchi, A., 2013. Spiral Artery Remodeling in Preeclampsia Revisited. *Hypertens*, 62, pp.1013-4.
- Cai, H., Harrison, D.G. (2000). Endothelial Dysfunction in Cardiovascular Diseases The Role of Oxidant Stress. *Circulation Research*, 87, 840-844.
- Camarena, PEE., Garcia,B., Panduro BJD., Pascoe GS., Madrigal SAJ., Garcia P., Totsuka,S. 2016. Efficacy of L-Arginine for preventing preeclampsia in high risk pregnancies: A double-blind, randomized, clinical trial. *Hypertensive pregnancy*. 35(2): p217-25.
- Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. 1997. Effect of supplemental oral L-Arginine on exercise capacity in patients with stable angina pectoris. *Am J Cardiology*. 80(3):331-3.
- Chaiworapongsa T, Romero R, Espinoza J. (2004). Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. *Am J Obstet Gynecol* 2004; 190:1541.

- Chaiworapongsa, T., Chaemsaitong, P., Yeo, L., & Romero, R. (2014). Pre-eclampsia part 1: current understanding of its pathophysiology. *Nat Rev Nephrol*, 10(8): 466–480.
- Chalid, M. T. (2016). *Upaya Menurunkan Angka Kematian Ibu: Peran Petugas Kesehatan*. Makassar: ResearchGate.
- Chen, J., Sheehan, P., Brennecke, S. & Keogh, R., (2012). Vessel *remodeling*, pregnancy hormones and extravillous trophoblast function. *Mol Cell Endocrinol*, 349, pp.138-44.
- Comiskey, M., (2003). Evidence that HLA-G is the functional homolog of mouse Qa-2, the Ped gene product. *Hum Immunol*, 64(11), pp.999-1004.
- Croy, B., Yamada, A., DeMayo, F. & Adamson, S., (2014). *The Guide to Investigation of Mouse Pregnancy*. London: Academic Press.
- Cudmore, M., Ahmad, S., Al-Ani, B., Fujisawa, T., Coxall, H., Chudasama, K., Devey, LR., Wigmore, SJ., Abbas, A., Hewett, PW., Ahmed, A. (2007). Negative Regulation of Soluble Flt-1 and soluble Endoglin Release by heme oxygenase-1. *Circulation*. 2007 Apr 3; 115(13): 1789-97.
- Cunningham, F., Leveno, K., Bloom, S., Dashe, J., Spong, C., Hoffman, B., Casey, B., 2018. *Williams Obstetrics*. 25th ed. New York: McGraw-Hill Education.
- de Boo HA, van Zijl PL, Smith DE, Kulik W, Lafeber HN. 2005. Arginine and mixed amino acids increase protein accretion in the growth-restricted and normal ovine fetus by different mechanisms. *Pediatr Res* 58: 270-277
- Dorniak-Wall, T. (2014). The role of L-arginine in the prevention and treatment of pre-eclampsia: a systematic review of randomised trials. *Journal of human hypertension*, 28(4), p.230.
- Esteve-Valverde, E., Ferrer-Oliveras, R., Gil-Aliberas, N., Baraldès-Farré, A., Llurba, E., & Alijotas-Reig, J. (2018). Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. *Obstetrical And Gynecological Survey*, Volume 73, Number 1.
- Fisher, SJ. (2015). Why is placentation abnormal in preeclampsia. *Am J Obstet Gynecol*. 213(4 Suppl):S115-22. doi: 10.1016/j.ajog.2015.08.042.
- Furuya, M., Ishida, J., Aoki, I., Fukamizu, A. 2008. Pathofisiology of placentation abnormalities in pregnancy-induced hypertension. *Vascular Health and Management* 4(6), pp. 1301-1313
- Gilbert JS, Ryan MJ, LaMarca BB, (2008). Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. *Am J Physiol Heart Circ Physiol*; 294:H541. 140.
- Gregory, A., Xu, G., Sotov, V. & Letarte, M., 2014. The enigmatic role of endoglin in the placenta. *Placenta*, 1(35), pp.S93-99.

- Gui, S., 2014. Arginine supplementation for improving maternal and neonatal outcomes in hypertensive disorder in pregnancy: a systematic review. *Journal of the Renin-Angiotensin-Aldosterone System*, 15(1), pp.88-96.
- Hartwell, L., 2011. *Mus musculus: Genetic Portrait of the House Mouse*. In *Genetics: From Genes to Genomes*. 4th ed. McGraw-Hill. pp.109-41.
- Hedge, C., 2012. The Use of L-Arginine in the Management of Pre-Eclampsia and Intrauterine Growth Restriction. *The Journal of Obstetrics and Gynecology of India*, 62(1), pp.1-2.
- Huppertz, B. 2007. Placental Origins of Preeclampsia: Challenging the Current Hypothesis. *Hypertension (American Heart Association Inc)*, 51(1): 970-975.
- ISSHP. (2014). The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. pp97-104.
- Jim, B., Karumanchi, SA. 2017. Preeclampsia: pathogenesis, prevention, and long-term complications. *Semin. Nephrol.* 37 386–397.
- Kadyrov, M., Kingdom, J. & Huppertz, B., 2006. Divergent Trophoblast Invasion and Apoptosis in Placental Bed Spiral Arteries from Pregnancies Complicated by Maternal Anemia and Early-onset Preeclampsia/Intrauterine Growth Restriction. *AJOG*, 194, pp.557-63.
- Kemse, N. G., Kale, A. A., Joshi, S. R. 2014. A combined supplementation of omega-3 fatty acids and micronutrients (folic acid, vitamin B12) reduces oxidative stress markers in a rat model of pregnancy induced hypertension. *PLoS One*, 9, e111902.
- Khalil, R. A., Crews, J. K., Novak, J., Kassab, S., Granger, J. P. 1998. Enhanced vascular reactivity during inhibition of nitric oxide synthesis in pregnant rats. *Hypertension* 31, 1065–1069.
- Khalil, R. A., Granger, J. P. 2002. Vascular mechanisms of increased arterial pressure in preeclampsia: Lessons from animal models. *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology*, 283, R29–R45
- Kim, M., Park, HJ., Seol, JW., Jang, JY., Cho, Y., Lydon, JP., DeMayo, FJ., Shibuya, M., Ferrara, N., Sung, H., Nagy, A., Alitalo, K., Koh, GY. 2013. VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodeling during pregnancy. *EMBO Mol Med*, 5, pp.1415-30.
- Knowles, RG., Moncada, S. 1994. *Nitric oxide synthases in mammals*. *Biochem J* 298:249–258
- Kuklina, E., Ayala, C. & WM, C., 2009. Hypertensive disorders and severe obstetric morbidity in the United States. *Obstet Gynecol*, 113(6), pp.1299-306.

- Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, 2009.. A Prospective cohort study of the value of maternal plasma concentration of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patient destined to develop preeclampsia. *Journal of Maternal and Fetal Neonatal Medicine*; 22 (11): 1021-38
- Kusumawati, R., Jusup, R. & Sulastomo, H., 2015. L-arginine Decreases Hypertension in Preeclampsia Model of Rats. *Journal of Hypertension*, 33, p.e28.
- Lain KY, Roberst JM. Contemporary concept of Pathogenesis and Management of Preeclampsia. *JAMA* 2002; 287:3183
- Laresgoiti-Servitje, E., N, G.-L. & Olson, D., 2010. An immunological insight into the origins of preeclampsia. *Hum Reprod Update*, 16(5), pp.510-24.
- Lei, H., Zhiling, Y., 2014. Antepartum or Immediate Postpartum Renal Biopsy Preeclampsia of Pregnancy, New Morphologic and Clinical Findings. *IntJClinExpPathol*. 7(8): 5129-5143
- Levine RJ, Qian C, Leshane ES, 2004. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia, *Am J Obstet Gynecol* 2004; 190:707
- Levine RJ, Qian C, Maynard SE, et al. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. *Am J Obstet Gynecol* 2006: 194:1034.
- Levine RJ, Maynard SE, Qian C, 2007. Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med* 2004; 350:672.
- López-Jaramillo, P. 2000. Calcium, nitric oxide and preeclampsia. *Sem Perinatol* 24: 33–36
- Lopez-Jaramillo, P., Casas, J.P., Serrano, N. 2001. Preeclampsia: from epidemiological observations to molecular mechanisms. *Braz J Med Biol Res* 34: 1227–1235
- Lopez-Jaramillo, P., 2008. The role of the L-arginine-nitric oxide pathway in preeclampsia. *Therapeutic Advances in Cardiovascular Disease*, 2(4), pp.261-75.
- Lopez-Jaramillo, P., Narvaez, M., Calle, A., Rivera, J., Jacome, P., Ruano, C. 1996. Cyclic guanosine 3',5' monophosphate concentrations in pre-eclampsia: effects of hydralazine. *Br J Obstet Gynaecol* 103:33–38
- Lowe, SA., Brown, MA., Dekker, GA., Gatt, S., McLintock, CK., McMahon, LP. et al. (2009). Guidelines for the management of hypertensive disorders of pregnancy 2008. *Aust N Z J Obstet Gynaecol* 49:242–246.
- Lowe, DT. 2000. Nitric Oxide Dysfunction in the Pathophysiology of Preeclampsia. *NITRIC OXIDE: Biology and Chemistry* Vol. 4, No. 4, pp.

441–458. doi:10.1006/niox.2000.0296, available online at <http://www.idealibrary.com>

- Lukito, JS, Dewi, P, 2007. Gambaran Histopatologi Arteri Spiralis Alas Plasenta pada Preeklampsia/Eklampsia dan Kehamilan Normotensif. *Majalah Kedokteran Nusantara* 40(3), halaman 173-179.
- Masoudian P, Nasr A, de Nanassy J, et al. Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis. *Am J Obstet Gynecol* 2016; 214:328.
- Matthiesen, L. *et al.*, 2005. Immunology of preeclampsia. *Chem Immunol Allergy*, 89, pp.49-61.
- Maynard SE, Min JY, Merchan J, et al. 2011. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest* 2003; 111:649.
- McCord, N., 2006. System y+ arginine transport and NO production in peripheral blood mononuclear cells in pregnancy and preeclampsia. *Hypertension*, 47(1), pp.109-15.
- Merviel, P., 2004. Pathophysiology of preeclampsia: link with implantation disorders. *Eur J Obstet Gynecol Reprod Biol*, 115, pp.134-47.
- Mittal, R., Satwant, K., & Mittal, N. (2013). Review Article L – Arginine Supplementation in Intrauterine Growth Retardation OF. 2(3), 1569–1572.
- Morris, SM, Billiar, TR. 1994. New insights into the regulation of inducible nitric oxide synthesis. *Am J Physiol* 266:E829–E839
- Norbert W, Bernard B, Elie A, Vassilis T, and Henri-Jean P. 2009. L-Arginine treatment for severe vascular fetal intrauterine growth restriction: randomized double-blind controlled trial. *Clinical Nutrition*. 28:243-48.
- Patil MD. 2016. Arginine dependence of tumor cells: targeting a chink in cancer's armor. *Oncogene*. 35(38): 4957-72.
- Perez-Sepulveda, A., Torres, M., Khoury, M. & Illanes, S., 2014. Innate immune system and preeclampsia. *Front Immunol*, 5(244), pp.1-7.
- Phipps, E., Prasanna, D., Brima, W., Jim, B. 2016. Preeclampsia: Updates in Pathogenesis, Definitions, and Guideline. *Clin J Am Soc Nephro*. doi: 10.2215/CJN.12081115
- Pimentel, AML., Pereira, NR., Costa, CA., Mann, GE., Cordeiro, VSC., de Moura, RS. 2013. L-arginine-nitric oxide pathway and oxidative stress in plasma and platelets of patients with pre-eclampsia. *Hypertension Research* 1–6. doi:10.1038/hr.2013.34

- Podjarny, E., Losonczy, G. & Baylis, C., 2004. Animal models of preeclampsia. in *Seminars in nephrology*, 24(6), pp.596-606.
- Pope WF. 1994. Embryonic mortality in swine. Embryonic mortality in domestic species. In: Geisert RD, editor. Boca Raton (FL): CRC: 53-76
- Possomato-viera, JS., Khalil, RA. 2016. Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. Elsevier. <http://dx.doi.org/10.1016/bs.apha.2016.04.008>
- Powe, C. E., Levine, R. J., & Karumanchi, S. A. (2012). Preeclampsia, a Disease of the Maternal Endothelium The Role of Antiangiogenic Factors and Implications for Later Cardiovascular Disease. *Circulation* , 2856-2869.
- Pritchard, J., & MacDonald, P. 1980. Williams Obstetrics 16th ed. (16th ed.). New York: Appleton-Century-Crofts.
- Prins, J., 2012. Reproductive immunology: Modulation of immune responses in pregnancy and effects on pregnancy outcome. Thesis. Groningen: University of Groningen.
- Pulido C, Benavides G, Baron P, Gonzalez P, Saray M, Padilla G, & Sutto T, 2015. Efficacy of L-Arginine for preventing preeclampsia in high-risk pregnancies: A double blind, randomized, clinical trial. doi.org/10.3109/10641955.2015.1137586, p 1-9
- Rajakumar A, Doty K, Daftary A, et al. Impaired oxygen-dependent reduction of HIF-1 α and -2 α proteins in pre-eclamptic placentae. *Placenta* 2003; 24:199-212.
- Rajapakse, N. & Mattson, D., 2009. Role of L-arginine in nitric oxide production in health and hypertension. *Clinical and Experimental Pharmacology and Physiology*, 36(3), pp.249-55.
- Rana S, Rajakumar A, Geahchan C, et al. Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1 α pathway. *FASEB J* 2014; 28:4324.
- Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. *Circulation* 2012; 125:911.
- Ramesar, S. V., Mackraj, I., Gathiram, P., Moodley, J. 2011. Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley rats. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, 157, 136–140
- Redman, C. & Sargent, I., 2009. Placental stress and pre-eclampsia: A revised view. *Placenta*, 23, pp.s38-42.

- Reynold, C., Mabie, W., Sibai, B. 2003. Hypertention States of Pregnancy. In: DeCherney, Nathan L, editors. *Current Obstetric and Gynecologic Diagnosis and Treatment*. 9 ed. Boston: *McGraw-Hill*.
- Rytlewski, K., Olszanecki, R., Korbut, R. & Zdebski, Z., 2005. Effects of prolonged oral supplementation with L-arginine on blood pressure and nitric oxide synthesis in preeclampsia. *European Journal of Clinical Investigation*, 35, pp.32-37.
- Roeshadi. Upaya menurunkan angka kesakitan dan angka kematian ibu oada penderita preeclampsia dan eklampsia. Pidato pengukuhan jabatan guru besar Fakultas Kedokteran Universitas Sumatera Utasa Medan; 2006
- Satgas Penakib Jawa Timur. 2016. Penatalaksanaan Preeklampsia dan Perdarahan Postpartum
- Schiessl, B., Strasburger, C., Bidlingmaier, M., Mylonas, I., Jeschke, U., Kainer, F. et al. 2006. Plasma- and urine concentrations of nitrite/nitrate and cyclic Guanosinemonophosphate in intrauterine growth restricted and preeclamptic pregnancies. *Arch Gynecol Obstet* 274: 150–154..
- Schjenken, J. et al., 2012. Mechanism of maternal immune tolerance during pregnancy. In J. Zheng, ed. *Recent advances in research on the human placenta*. Madison: InTech. pp.211-42.
- Schoots, MH., Gordijn, SJ., Scherjon, SA., van Goor, H., Hillebrands, J-L. 2018. Oxidative stress in placental pathology. *Placenta*. doi: 10.1016/j.placenta.2018.03.003
- Serrano, N.C., Casas, J.P., Diaz, L.A., Paez, C., Mesa, C.M., Cifuentes, R. et al. 2004. Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study. *Hypertension* 44:702–707.
- Shah, D., 2007. Preeclampsia: New insight. *Curr Opin Nephrol Hypertens*, 16, pp.213-20.
- Sibai, B., 2012. Etiology and management of postpartum hypertension-preeclampsia. *AJOG*.
- Sibai, B., Dekker, G. & Kupferminc, M., 2005. Pre-eclampsia. *Lancet*, 365, pp.785-99.
- Sibai, BM. 2012. Etiology and management of postpartum hypertension-preeclampsia. *Am J Obstet Gynecol*. 206(6):470-5. doi: 10.1016/j.ajog.2011.09.002
- Sirait, A., 2012. Prevalensi hipertensi pada kehamilan di Indonesia dan berbagai faktor yang berhubungan (Riset Kesehatan Dasar 2007). *Buletin Penelitian Sistem Kesehatan*, 15(2), pp.103-9.

- Sladek, SM., Magness, RR., Conrad, KP. 1997. Nitric Oxide and Pregnancy. *Am. J. Physiol.* 272 Regzdatory Integrative Comp. *Physiol.* 41: R441-R463,199
- Slaghekke, F., Dekker, G. and Jeffries, B. 2006. Endogenous inhibitors of nitric oxide and preeclampsia: a review. *J Matern Fetal Neonatal Med* 19: 447–452
- Soares, M. jika, 2012. Rat Placentation: An Experimental Model for Investigating the Hemochorial Maternal-fetal Interface. *Placenta*, 33, pp.233-43.
- Soares, M. 2014. Adaptive Mechanism Controlling Uterine Spiral Artery *Remodeling* during the Establishment of Pregnancy. *Int J Dev Biol*, 58, pp.247-59.
- Soetrisno, Sulistyowati, S. & Wibowo, A., 2017. L-arginine improves uterine spiral arterial wall thickness in mouse models of preeclampsia. *Universa Medicina*, 36(2), pp.131-38.
- Staff AC, Braekke K, Johnsen GM, et al. 2013. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. *Am J Obstet Gynecol* 2007; 197:176.e1.
- Steegers, EAP., Dadelszen, PV., Duvkot, JJ., Pijnenborg, R. 2010. Pre-eclampsia. *Lancet*; 376: 631–44. doi:10.1016/S0140-6736(10)60279-6
- Sulistyowati, S., Abadi, A. & Wijati, 2010. Low Class Ib (HLA-G/Qa-2) MHC Protein Expression againts Hsp-70 and VCAM-1 Profile on Preeclampsia. *Indones J Obstet Gynecol*, 34(3), pp.103-7.
- Tanetta DS, Dragovic RA, Gardiner C, et al. Characterisation of syncytiotrofoblast vesicles in normal pregnancy and preeclampsia expression of Flt-1 and ebdoglin. *PLoS One* 2013; 8:e56754.
- Tapiera, H., Mathe, G., Couvreur, P. & Tew, K., 2002. L-Arginine. *Biomedicine & Pharmacotherapy*, 56(9), pp.439-45.
- Thangaratinam, S., Langenveld, J., Mol, BW., Khan, KS. 2011. Prediction and primary prevention of pre-eclampsia. *Elsevier* vol 25, Issue 4, pages 419-433. <https://doi.org/10.1016/j.bpobgyn.2011.02.008>
- Thureen, P., Baron, K., Fennessey, PV., Hay, W., 2002, Ovine Placental and fetal arginine metabolism at normal and increased maternal plasma arginine concentrations. *Pediatr Res* 51: 464-471.
- Valverde, EE., Oliveras, RE., Aliberas, NG., Farre, AB., Llurba, E., Reig, JA, 2018. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. *Obstetrical And Gynecological Survey Wolters Kluwer Health* Volume 73, Number 1
- Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. *Nat Med* 2006; 12:642.

- Walker, J.J. 2000. Pre-eclampsia. *Lancet* 356:1260–1265.
- Wang K., Ahmad S., Cai M., Rennie J., Fujisawa T., Crispi F., et al. 2013. Dysregulation of hydrogen sulfide producing enzyme cystathionine gamma-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia. *Circulation*. 127:2514–252.
- Wardhana, M. & Laksana, M.A.C., 2015. Gambaran Pelayanan Antenatal pada Kasus Hipertensi dalam Kehamilan Sebelum Dirujuk ke RSUD Dr Soetomo. In Pertemuan Ilmiah Tahunan Himpunan Obstetri dan Ginekologi Sosial Indonesia VIII. Banjarmasin, 2015.
- Wardhana, M., 2015. Decreasing of placental progesterone induced blocking factor expression and spiral artery remodeling disturbance in mice preeclampsia model. *Pregnancy Hypertension*, 5(3), pp.242-43.
- Wardhana, M.P., Dachlan, E.G. & Dekker, G., 2018. Pulmonary edema in preeclampsia: an Indonesian case-control study. *The Journal of Maternal-Fetal & Neonatal Medicine*, 31(6), pp.689-95.
- Wardhana, M. P. (2019). Perbedaan Tekanan Darah dan Ekspresi Transforming Growth Factor- β 1 Plasenta antara Mencit Bunting normal, Mencit Model Preeklampsia Tanpa dan Dengan Pemberian L-Arginine.
- WHO. (2011). Prevention and treatment of pre-eclampsia and eclampsia.
- Wooding, P. & Burton, G., 2008. Comparative Placentation: Structures, Functions and Evolution. Berlin: Springer Science & Business Media.
- Williams, DJ., Vallance, PJ., Neild, GH., Spencer, JA., Imms, FJ. 1997. Nitric oxide-mediated vasodilation in human pregnancy. *The American Journal of Physiology*, 272, H748–H752
- Winer N, Branger B, Azria A. 2009. L-Arginine treatment for severe vascular fetal intrauterine growth restriction: a randomized double-blind controlled trial. *Clinical Nutrition*. 28(3):243-249. doi: 10.1016/j.clnu.2009.03.007.
- Wu, Bazer FW, Wallace JM, Spencer TE. 2006. Board-invited review: intrauterine growth retardation; implications for the animals sciences. *J anim Sci* 84: 2316-2337.
- Xia Ma, F., Han, ZC. 2005. Statins, Nitric Oxide and Neovascularization. *Cardiovascular Drug Reviews* Vol. 23, No. 4, pp. 281–292. Neva Press, Branford, Connecticut
- Xiang., 2005; Xiang, W., Chen, H., Xu, X., Zhang, M. and Jiang, R. 2005. Expression of endothelial nitric oxide synthase traffic inducer in the placentas of women with pre-eclampsia. *Int J Gynaecol Obstet* 89: 103–107

- Yamamoto, T., Suzuki, Y., Kojima, K., Suzumori, K. 2005. Reduced flow-mediated vasodilation is not due to a decrease in production of nitric oxide in preeclampsia. *Am J Obstet Gynecol* 192: 558–563.
- Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. *N Engl J Med* 2016; 374:13.
- Zhou Y., Damsky, CH., Fisher, SJ. 1997. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?. *J Clin Invest.* 99(9):2152-64.